We are a drug developer with unique expertise focusing on diseases with no alternative treatments


Karlsson JOG, Adolfsson K, Thelin B, Jynge P, Andersson RGG, Falkmer UG. First clinical experience with the MRI contrast agent and SOD mimetic mangafodipir as an adjunct in cancer chemotherapy – a translational study.
Transl Oncol.2012;5:32-38.

Kurz T, Grant D, Andersson RGG, Towart R, De Cesare M, Karlsson JOG. Effects of MnDPDP and ICRF-187 on doxorubicin-induced cardiotoxicity and anticancer activity.
Transl Oncol. 2012;5:252-259.

Karlsson JOG, Kurz T, Flechsig S, Näsström J, Andersson, RGG. Superior therapeutic index of calmangafodipir in comparison to mangafodipir as a chemotherapy adjunct.
Transl Oncol. 2012;5:492-502.

Näsström J. Breaking away from the norm: a new perspective on cancer therapeutics.
Drug Discov. Today 2014;19(10):1508-9.

Karlsson J-E, El-Saadi W, Ali M, Puskar W, Skogvad P, Engvall JE, Andersson RG, Maret E, Jynge P. Mangafodipir as a cardioprotective adjunct to reperfusion therapy: a feasibilty study in patients with ST-segment elevation myocardial infarction.
Eur. Heart J. 2015;1:39-45.

Karlsson JOG, Ignarro LJ, Lundström I, Jynge P, Almén T. Calmangafodipir [Ca4Mn(DPDP)5], mangafodipir (MnDPDP) and MnPLED with special reference to their SOD mimetic and therapeutic properties.
Drug Discov. Today 2015;20(4):411-21.

Glimelius B, Manojlovic N, Pfeiffer P, Mosidze B, Kurteva G, Karlberg M, Mahalingam D, Buhl Jensen P, Kowalski J, Bengtson M, Nittve M, Näsström J. Persistent prevention of oxaliplatin-induced peripheral neuropathy using calmangafodipir (PledOx®): a placebo-controlled randomised phase II study (PLIANT).
Acta Oncol. 2018;57(3):393-402.



Contact us

Address: Grev Turegatan 11 C, 114 46 Stockholm, Sweden

Phone: +46 8 679 72 10

E-mail: info@pledpharma.com